Immunovant Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $469.8M | $493.8M |
| FY2023 | — | $362.5M | $376.5M |
| FY2024 | — | $617.8M | $635.4M |
| FY2025 | — | $707.4M | $714.0M |
| FY2026 | — | $852.6M | $902.1M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $469.8M | $493.8M |
| FY2023 | — | $362.5M | $376.5M |
| FY2024 | — | $617.8M | $635.4M |
| FY2025 | — | $707.4M | $714.0M |
| FY2026 | — | $852.6M | $902.1M |